Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00201422
Status:
COMPLETED
Last Update Posted:
2016-03-28
First Post:
2005-09-13
Brief Title:
Eradication of Helicobacter Pylori in the Management of Stage IE IIE-1 Primary Low-grade B Cell Lymphoma of MALToma
Sponsor:
National Health Research Institutes Taiwan
Organization:
National Health Research Institutes Taiwan
Study Overview
Official Title:
Eradication of Helicobacter Pylori in the Management of Stage IE IIE-1 Primary Low-grade B Cell Lymphoma of Mucosa-associated Lymphoid Tissue Type of The Stomach
Status:
COMPLETED
Status Verified Date:
2016-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the therapeutic effectiveness of H pylori eradication in stage IE IIE-1 primary low-grade B cell lymphoma of MALT of the stomach
Detailed Description:
To investigate the prevalence of H pylori infection in patients with early stage of primary low-grade B cell lymphoma of MALT of the stomach in Taiwan
-To evaluate the therapeutic effectiveness of H pylori eradication in stage IE IIE-1 primary low-grade B cell lymphoma of MALT of the stomach
To evaluate the efficacy of Helicobacter pylori eradication therapy with respect to objective regression rate and time to disease progression of primary low-grade gastric MALToma
To estimate any differences in therapeutic efficacy related to different stage of diseaseeg stage IE vs stage IIE-1
To identify the causes of treatment failure such as the stage of tumor the presence of large cell component andor persistent reactivation or reinfection of H pylori etc
-To evaluate the therapeutic effectiveness of H pylori eradication in stage IE IIE-1 primary low-grade B cell lymphoma of MALT of the stomach
To evaluate the efficacy of Helicobacter pylori eradication therapy with respect to objective regression rate and time to disease progression of primary low-grade gastric MALToma
To estimate any differences in therapeutic efficacy related to different stage of diseaseeg stage IE vs stage IIE-1
To identify the causes of treatment failure such as the stage of tumor the presence of large cell component andor persistent reactivation or reinfection of H pylori etc
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None